Cutter Capital Management LP Has $14.22 Million Holdings in Insmed, Inc. $INSM

Key Points

• Cutter Capital Management LP has reduced its stake in Insmed, Inc. by 11.6%, selling 24,500 shares and now owning 186,384 shares, which accounts for 6.2% of its investment portfolio.
• Insmed's recent earnings report showed a loss of ($1.70) per share, which was $0.40 below the consensus estimate, but the company recognized a 18.9% year-over-year revenue increase.
• Several analysts have increased their price targets for Insmed, with Mizuho setting a target of $165.00 and a majority giving the stock a rating of Buy, indicating strong confidence in its future performance.

Cutter Capital Management LP cut its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 11.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 186,384 shares of the biopharmaceutical company's stock after selling 24,500 shares during the quarter. Insmed comprises approximately 6.2% of Cutter Capital Management LP's holdings, making the stock its 5th largest position. Cutter Capital Management LP owned about 0.10% of Insmed worth $14,219,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. raised its holdings in shares of Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 221 shares in the last quarter. Elequin Capital LP bought a new stake in Insmed in the fourth quarter worth $28,000. NBC Securities Inc. acquired a new position in Insmed during the first quarter worth $49,000. Versant Capital Management Inc raised its holdings in Insmed by 546.3% during the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 590 shares in the last quarter. Finally, Signaturefd LLC raised its holdings in Insmed by 60.0% during the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 325 shares in the last quarter.

Wall Street Analysts Forecast Growth

INSM has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price target on Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 20th. Citigroup upgraded Insmed to a "buy" rating in a report on Tuesday, June 10th. Truist Financial increased their price target on Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a report on Thursday, August 14th. The Goldman Sachs Group boosted their price objective on shares of Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Finally, Bank of America upped their price objective on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $139.86.

Insider Activity

In other Insmed news, CEO William Lewis sold 129,805 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $100.39, for a total value of $13,031,123.95. Following the completion of the transaction, the chief executive officer owned 233,924 shares of the company's stock, valued at $23,483,630.36. This represents a 35.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total value of $9,264,648.24. Following the completion of the sale, the insider owned 89,407 shares of the company's stock, valued at $8,352,401.94. This represents a 52.59% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 477,554 shares of company stock valued at $49,433,687. Corporate insiders own 3.00% of the company's stock.

Insmed Stock Performance

NASDAQ:INSM traded up $0.35 during trading hours on Tuesday, hitting $147.03. 553,235 shares of the company traded hands, compared to its average volume of 2,783,318. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $147.51. The firm has a 50-day moving average of $115.56 and a 200 day moving average of $90.20. The stock has a market capitalization of $31.08 billion, a price-to-earnings ratio of -25.74 and a beta of 0.96.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The company had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business's revenue for the quarter was up 18.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.94) earnings per share. Insmed has set its FY 2025 guidance at EPS. On average, analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.